Application of evodiamine in preparation of pancreatic cancer cell activity inhibitor

Through the application of Evodoripine, it uses its ability to inhibit the proliferation, migration and apoptosis of pancreatic cancer cells, and by inhibiting the JAK2/STAT3 signaling pathway, the problem of drug resistance and side effects of existing pancreatic cancer treatment drugs has been solved, providing a An effective treatment plan for pancreatic cancer with less side effects.

CN118924754AInactive Publication Date: 2024-11-12HANGZHOU FIRST PEOPLES HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410988306.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing pancreatic cancer treatment drugs are prone to tumor resistance after several weeks of treatment, and have greater side effects. There are few studies on the treatment of inhibiting the JAK2/STAT3 signaling pathway.

Method used

Evodoribrine is used as an activity inhibitor. In vitro and in vivo experiments, it can effectively inhibit the proliferation, migration, cycle and apoptosis of pancreatic cancer cells. The specific concentration is between 40μM and 80μM. The tumor cells are inhibited by inhibiting the JAK2/STAT3 signaling pathway. development.

Benefits of technology

Evodoribrine significantly inhibits pancreatic cancer cells in both in vivo and in vitro experiments, with a semi-inhibitory concentration of 70μM, with minor side effects, providing a new natural compound as a candidate for pancreatic cancer treatment, extending the patient's life and inhibiting The progression of tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924754A_ABST
    Figure CN118924754A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medical chemistry, in particular to application of evoblastine in preparation of a pancreatic cancer cell activity inhibitor, pancreatic cancer cells are pancreatic cancer cell lines CFPAC-1 and SW1990, the evoblastine serves as a JAK2 / STAT3 signal channel inhibitor, proliferation, migration and cell cycle of the pancreatic cancer cells are inhibited, and the activity of the pancreatic cancer cells is inhibited. According to the present invention, the pharmaceutical composition has effects of pancreatic cancer treatment and pancreatic cancer apoptosis inducing so as to achieve the pancreatic cancer treatment effect, the evodiamine has significant pancreatic cancer resistance in the in-vivo animal experiment and the in-vitro cell experiment, the half inhibition concentration of the four pancreatic cancer cells is 70 [mu] M, and the development of more effective drugs based on the evodiamine is solved; the side effect is relatively small.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of pharmaceutical chemistry, and in particular to an application of evodia rutaecarpine in the preparation of a pancreatic cancer cell activity inhibitor. Background Art

[0002] Among clinical digestive system diseases, pancreatic cancer is a common malignant tumor. Pancreatic cancer is a malignant tumor of the exocrine pancreas. Its main clinical manifestations include abdominal pain, weight loss, jaundice, etc. Most patients cannot undergo surgical resection after diagnosis and die within about half a year. The 5-year survival rate is less than 5%. Due to its high malignancy, difficulty in treatment, and poor prognosis, it is still the most difficult cancer to treat in oncology. At present, the etiology and pathogenesis of pancreatic cancer have not been clearly defined. Previous epidemiological survey data show that the risk factors for pancreatic cancer include smoking, high-fat and high-protein diets, genetics, diabetes, chronic pancreatitis, cholelithiasis, alcoholism, and endocrine changes, but the specific pathological molecular mechanisms remain to be explored.

[0003] At present, gemcitabine and fluorouracil are the most commonly used first-line treatment drugs for pancreatic cancer in clinical practice. For such patients who need chemotherapy, tumor resistance often occurs after a few weeks of treatment, and other effective drugs need to be replaced to prolong the patient's life. However, the choice of alternative drugs is very limited, so the development of more effective pancreatic cancer treatment drugs with fewer side effects is one of the key issues that need to be urgently addressed in clinical and scientific research. There have been no previous research results on the inhibition of pancreatic cancer by evodia rutaecarpine, nor have there been any studies on the treatment of tumors by inhibiting the JAK2 / STAT3 signaling pathway by evodia rutaecarpine.

[0004] In view of the above-mentioned defects, the inventors of the present invention finally obtained the present invention after a long period of research and practice. Summary of the invention

[0005] The purpose of the present invention is to solve the problem of how to develop more effective pancreatic cancer therapeutic drugs with fewer side effects based on evodiamine, and provide an application of evodiamine in the preparation of a pancreatic cancer cell activity inhibitor.

[0006] In order to achieve the above object, the present invention discloses an application of evodiamine in the preparation of anti-pancreatic cancer activity, and the structural formula of the evodiamine is as follows:

[0007]

[0008] The pancreatic cancer cells are pancreatic cancer cell lines CFPAC-1 and SW1990.

[0009] In an in vitro test, the effective concentration of evodiamine in the inhibitor is ≥40 μM, and the half-dose inhibitory concentration value of evodiamine on pancreatic cancer cells for 24 hours is 70 uM.

[0010] The use concentration of evodia rutaecarpine in the inhibitor is 5 mg / kg to 10 mg / kg.

[0011] The invention also discloses an application of evodiamine in preparing CFPAC-1 and SW 1990 cell migration ability inhibitors.

[0012] In the in vitro test, the effective concentration of Evodia rutaecarpa in the inhibitor is 40 μM to 80 μM, and the effective time is 24 hours.

[0013] The invention also discloses an application of evodia rutaecarpine in preparing CFPAC-1 and SW 1990 cell cycle inhibitors.

[0014] In the in vitro test, the effective concentration of Evodia rutaecarpa in the inhibitor is 40 μM to 80 μM, and the effective time is 24 hours.

[0015] The invention also discloses an application of evodiamine in preparing CFPAC-1 and SW 1990 cell apoptosis inducers.

[0016] In the in vitro test, the effective concentration of Evodia rutaecarpa in the inhibitor is 40 μM to 80 μM, and the effective time is 24 hours.

[0017] Compared with the prior art, the beneficial effect of the present invention is that the present invention provides an application of evodiamine in the preparation of anti-pancreatic cancer activity, which is specifically reflected in that evodiamine has obvious anti-pancreatic cancer effects in both in vivo animal experiments and in vitro cell experiments, and the half-inhibitory concentration in four pancreatic cancer cells is 70 μM. In addition, the present invention discloses the way in which evodiamine inhibits pancreatic cancer, which inhibits the development of tumor cells by inhibiting the JAK2 / STAT3 signaling pathway. The present invention is expected to provide candidate drugs for natural compounds as pancreatic cancer treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 is the structural formula of evodia rutaecarpine;

[0019] Figure 2 The ability of evodia rutaecarpine to inhibit the proliferation of pancreatic cancer, where A is the activity graph of pancreatic cancer cells, and B is the cell graph stained with EdU;

[0020] Figure 3 Evodiamine inhibits the migration ability of pancreatic cancer;

[0021] Figure 4 Evodia rutaecarpine blocks the pancreatic cancer cell cycle at the G2 / M phase;

[0022] Figure 5 Evodiamine induces apoptosis of pancreatic cancer cells;

[0023] Figure 6 Evodia rutaecarpine inhibits pancreatic cancer by inhibiting the JAK2 / STAT3 signaling pathway;

[0024] Figure 7 Evodia rutaecarpine can inhibit the progression of pancreatic cancer in mice. DETAILED DESCRIPTION

[0025] The above and other technical features and advantages of the present invention are described in more detail below in conjunction with the accompanying drawings.

[0026] 1. Evodia rutaecarpine can inhibit the proliferation of pancreatic cancer cells

[0027] 1. CCK8 reagent is used to detect the activity of cells after the action of different concentrations of evodia rutaecarpine

[0028] Two pancreatic cancer cell lines (ASPC-1, BXPC-3, CFPAC-1SW 1990) were planted in 96-well plates, with 3000 cells per well. Cell lines were treated with different evodia rutaecarpine concentrations (0 μM, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, 90 μM, 100 μM) and different treatment times (24 hours, 48 ​​hours, 72 hours), and CCK8 (10 μL per well, incubated at 37 degrees for 1 hour) was used to detect cell activity. The activity of all pancreatic cancer cells decreased with increasing concentration and time ( Figure 2 A), Both 24-hour IC50 values ​​are 70 μM.

[0029] 2. EdU detection of cell proliferation ability found that evodia rutaecarpine inhibited the proliferation of pancreatic cancer. EdU is a thymidine deoxynucleoside analog that can be incorporated into the DNA replication process and detect the proliferation ability of cells through fluorescence display. 1.7x10 4 The cells were incubated with culture medium containing evodia rutaecarpine (0μM, 40μM, 80μM), and then incubated with 10μM EdU culture medium after 19 hours. The cells were fixed with 4% paraformaldehyde and treated with Triton X-100 for 10 minutes. The cell nuclei were then stained with DAPI for 10 minutes in the absence of light. The proportion of cells stained with EdU increased with the decrease of evodia rutaecarpine concentration ( Figure 2 B), indicating that evodiamine can inhibit the proliferation ability of pancreatic cancer.

[0030] 2. Evodia rutaecarpine inhibits the migration of pancreatic cancer

[0031] The cell migration ability was detected by scratch test. CFPAC-1 and SW1990 cells (1×10 6 ) were inoculated in 6-well plates and cultured after observing that the cell fusion rate was between 90% and 100%. Serum-free RPM I-1640 medium was used for incubation for 24 hours to ensure that the interference of cell proliferation on the experiment was eliminated. The plate was washed with PBS to remove the suspended cells. CFPAC-1 and SW1990 cells were incubated with serum-free medium containing different concentrations of evodia rutaecarpine. The scratch healing was observed under a phase contrast microscope at 0 hours and 24 hours after treatment. The cell migration distance was calculated using ImageJ software. Results ( Figure 3 ) found that the migration ability of pancreatic cancer cells decreased with the increase of evodia rutaecarpine concentration.

[0032] 3. Evodia rutaecarpine blocks pancreatic cancer cell cycle at G2 / M phase

[0033] DNA quantification was performed using propidium iodide staining, and flow cytometry was used to detect cell cycle, CFPAC-1 and SW1990 (9 × 10 4 ) were inoculated overnight in a 6-well plate. Different concentrations of evodia rutaecarpine (0 μM, 40 μM, 80 μM) were used for treatment for 24 hours. After the cells were collected, they were centrifuged at 1000 rpm for 5 minutes and fixed with 70% pre-cooled ethanol for 12 hours. The cells were suspended in a PBS mixture containing 0.1% Triton X-100 and 1 mg / mL propidium iodide and incubated in the dark at room temperature for 30 minutes. The cell cycle distribution was detected using flow cytometry ( Figure 4 Each measurement captures at least 1×10 4 Using FlowJo software to process the cell cycle data, it was found that evodia rutaecarpine blocked the pancreatic cancer cell cycle at the G2 / M phase.

[0034] IV. Evodia rutaecarpine induces apoptosis of pancreatic cancer cells

[0035] Annexin V / PI staining was used to detect cell apoptosis. Pancreatic cancer cells (9×10 4 Each well) was inoculated in a 6-well plate and cultured overnight. After treatment with different concentrations of evodia rutaecarpine (0μM, 40μM, 80μM) for 24 hours, the treated cells were collected and washed with PBS. 5μL of Annexin V and 1μL of PI were added to each sample, incubated at room temperature in a dark environment for 15 minutes, and the excitation light at 530nm was detected by flow cytometry. The experimental results were analyzed using FlowJo software. The results showed that the proportion of apoptotic cells increased with the increase of evodia rutaecarpine concentration ( Figure 5 ).

[0036] 5. Evodia rutaecarpine inhibits JAK2 / STAT3 signaling

[0037] Pancreatic cancer cells (9×10 per well) 4 Each well) was inoculated overnight in a 6-well plate. Different evodiamine (0μM, 40μM, 80μM) were used for treatment for 24 hours. The samples were collected and lysed in PIPA lysis buffer with protease and phosphatase inhibitors, 5X Loading Buffer was added, and boiled at 95°C for denaturation for 5 minutes. The cell lysate was then electrophoresed with 10% SDS-page gel and transferred to a PVDF membrane. The membranes were incubated in the corresponding antibodies overnight, washed three times with TBST the next day, and the secondary antibody was added for 90 minutes. Color was developed in a chemiluminometer. It was found that the phosphorylated JAK2 and phosphorylated STAT3 signals increased significantly after the use of evodiamine, indicating that evodiamine can inhibit the JAK2 / STAT3 signaling pathway ( Figure 6 ).

[0038] 6. Evodiamine inhibits pancreatic cancer in vivo

[0039] Four-week-old nude mice were purchased from Shanghai SLAC Laboratory Animal Company. All nude mice were allowed free access to food and maintained in an SPF environment. The experimental protocol complied with the ethical standards of the Animal Care and Use Committee of Zhejiang Chinese Medical University. 6 CFPAC-1 cells were subcutaneously injected into the right side of the mouse. Two weeks later, mice with the same tumor size were randomly divided into three groups (control group, low-dose group, high-dose group). The mice received an injection of compound (dimethyl sulfoxide, 5 mg / kg, 10 mg / kg, gemcitabine 50 mg / kg) every three days, and the weight of the mice and the length and width of the tumor were measured. After 30 days, the mice were humanely killed, the tumors were removed and the tumor volume was measured (volume = 0.5 × length × width 2 ) and weight. The results showed that evodiamine can inhibit the proliferation of pancreatic cancer tumors in vivo ( Figure 7 ).

[0040] The above description is only a preferred embodiment of the present invention, which is only illustrative and not restrictive of the present invention. Those skilled in the art understand that many changes, modifications, and even equivalences may be made to the present invention within the spirit and scope defined by the claims of the present invention, but all of them will fall within the scope of protection of the present invention.

Claims

1. A use of evodiamine in the preparation of a pancreatic cancer cell activity inhibitor, characterized in that: The structural formula of the evodia rutaecarpine is as follows:

2. The use of evodiamine as claimed in claim 1 in the preparation of a pancreatic cancer cell activity inhibitor, characterized in that: The pancreatic cancer cells are pancreatic cancer cell lines CFPAC-1 and SW1990.

3. The use of evodiamine as claimed in claim 1 in the preparation of a pancreatic cancer cell activity inhibitor, characterized in that: In an in vitro test, the effective concentration of evodiamine in the inhibitor is ≥40 μM, and the half-dose inhibitory concentration value of evodiamine on pancreatic cancer cells for 24 hours is 70 uM.

4. The use of evodiamine as claimed in claim 1 in the preparation of a pancreatic cancer cell activity inhibitor, characterized in that: The use concentration of evodia rutaecarpine in the inhibitor is 5 mg / kg to 10 mg / kg.

5. An application of evodia rutaecarpine in the preparation of CFPAC-1 and SW 1990 cell migration ability inhibitors.

6. The use of evodiamine as claimed in claim 5 in the preparation of an inhibitor of CFPAC-1 and SW 1990 cell migration ability, characterized in that: In the in vitro test, the effective concentration of Evodia rutaecarpa in the inhibitor is 40 μM to 80 μM, and the effective time is 24 hours.

7. Use of evodia rutaecarpine in the preparation of CFPAC-1 and SW 1990 cell cycle inhibitors.

8. The use of evodiamine in the preparation of CFPAC-1 and SW 1990 cell cycle inhibitors as claimed in claim 7, characterized in that: In the in vitro test, the effective concentration of Evodia rutaecarpa in the inhibitor is 40 μM to 80 μM, and the effective time is 24 hours.

9. Use of evodiamine in the preparation of CFPAC-1 and SW 1990 cell apoptosis inducers.

10. The use of evodiamine as claimed in claim 9 in the preparation of CFPAC-1 and SW 1990 cell apoptosis inducers, characterized in that: In the in vitro test, the effective concentration of Evodia rutaecarpa in the inhibitor is 40 μM to 80 μM, and the effective time is 24 hours.